TARBP2 and hepatocellular carcinoma: Cell viability was decreased in Huh7/SR cells expressing wild‐type TARBP2 and those expressing TARBP2 ΔC4 (Fig. 2J), suggesting that TARBP2‐mediated sensitization of HCC cells to sorafenib treatment is miRNA‐independent.